MCW Cancer Center logo

Funding and Grants

Current Funding Opportunities

National Cancer Institute (NCI)

 Detection of Pathogen-Induced Cancer (DPIC) (R01) | Applications due July 10, 2015

Detection of Pathogen-Induced Cancer (DPIC) (R01)

This Funding Opportunity Announcement (FOA), issued by the National Cancer Institute (NCI), is to encourage research projects which focus on the interactions of carcinogenic pathogens with the human microbiome and the host for the detection of pathogen-induced cancer (DPIC). This FOA encourages research to assess molecular signatures associated with risk and early detection of pathogen-induced cancer and chronic inflammation associated with progression to invasive cancer.

Applications due July 10, 2015

 Imaging and Biomarkers for Early Cancer Detection (R01) | Applications due July 10, 2015

Imaging and Biomarkers for Early Cancer Detection (R01)

This Funding Opportunity Announcement (FOA) invites research project (R01) applications that combine imaging and biomarkers. The overall objective of this FOA is to facilitate collaborative imaging and biomarker research to improve cancer screening, early cancer detection and diagnosis by integrating multimodality imaging strategies and multiplexed biomarker methodologies.

Applications due July 10, 2015

Department of Defense (DOD)

 Ovarian Cancer Research Program (OCRP) - Investigator-Initiated Research Award | Applications due August 2015

Ovarian Cancer Research Program (OCRP) – Investigator-Initiated Research Award

Applications to the Fiscal Year 2015 (FY15) Ovarian Cancer Research Program (OCRP) are being solicited for the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate, by the U.S. Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA RDA Directorate manages and executes the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The executing agent for this Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP).

 Prostate Cancer Research Program | Applications due August and September 2015

Prostate Cancer Research Program

The mission of the FY15 PCRP is to find and fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of men experiencing the impact of the disease. Specifically, the PCRP seeks to promote highly innovative, groundbreaking research; high-impact research with near-term clinical relevance; multidisciplinary, synergistic research; translational studies to support the fluid transfer of knowledge between bedside and bench; research on patient survivorship and quality of life; the next generation of prostate cancer investigators through mentored research; and research on disparities in the incidence and mortality of prostate cancer.

Foundations & Organizations

 Children's Leukemia Research Association, Inc. (CLRA): Research Grants | Applications due June 30, 2015

Children's Leukemia Research Association, Inc. (CLRA): Research Grants

Each year, CLRA's Medical Advisory Committee, consisting of prominent internationally known and respected hematologists, reviews submitted research proposals from doctors nationwide. Using contributions, they fund research grants for doctors who are conducting the most promising research into leukemia, in the hopes of isolating the causes and finding a cure for this dread disease. Grants are limited to a maximum of $30,000 each.

Applications due June 30, 2015

 Lung Cancer Research Foundation (LCRF): Research Grants | Applications due July 1, 2015

Lung Cancer Research Foundation (LCRF): Research Grants

The Lung Cancer Research Foundation is proud to fund research that they believe will make major contributions toward better treatments, screening, and prevention of lung cancer. The maximum award is $75,000, for a one-year period.

LCRF has funded research in all of the following areas: Development of cutting-edge drugs; Identification of clinical applications for new lung cancer therapies; Identification of new biomarkers for treatment selection/resistance to therapy, prognosis, and early detection.

Support for investigators at all levels – from postdoctoral students to world leaders in the field of:

  • Psychosocial research into lung cancer
  • Prevention and early detection of lung cancer
  • Improved staging of lung cancer
  • Understanding of the pathways of lung cancer growth
  • Alternative/complementary therapy for lung

Applications due July 1, 2015

 The Hope Foundation: SWOG Early Exploration and Development (SEED) Fund | Applications due July 1, 2015

The Hope Foundation: SWOG Early Exploration and Development (SEED) Fund

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation. Awards are made from The Hope Foundation SEED Fund to encourage preliminary research that will potentially translate to future clinical trials or trial associated projects (translational medicine studies) within SWOG and the NCTN. These awards may assist investigators with projects that support the following types of studies: pre-clinical data, secondary data analysis from clinical trials, pilot and feasibility studies (including early stage clinical trials), small, self-contained research projects, or development of research methodology/technology. Any SWOG investigator eligible for NIH funding is encouraged to submit to this program. Individual projects may be funded for up to $50,000 (direct costs) and may be spent over a 1- or 2-year award period. Indirect costs are limited to a rate of 25%.

Applications due July 1, 2015

 Free to Breathe: Accelerate Clinical Trials Grant | Applications due July 17, 2015

Free to Breathe: Accelerate Clinical Trials Grant

Free to Breathe's goal is to fund pilot research projects that will investigate novel strategies to improve accrual of lung cancer patients to therapeutic cancer clinical trials by at least 50% within a defined healthcare facility, system or community. Project aims must have specific strategies focused on increasing accrual to lung cancer trials. Proposals must have a clear vision about how the pilot project, if successful, can be an expanded to other institutions for validation of the intervention or strategy. The intent of Free to Breathe is to fund projects that will be reproducible and implementable to a wider community, including other cancers. For 2015, Free to Breathe expects to support one to two awards of up to $100,000, including a maximum of 8% ($8,000) indirect costs. Grants will be paid over 2 years at $50,000 per year. The second year payments will be contingent on receipt and approval of written progress reports. Anticipated funding start date is November 1, 2015. The Free to Breathe Research Grant is to be used primarily for project support. No more than 20% of the requested budget may be used for salary and fringe benefits for the principal investigator(s). The Grant is not designed to supplement an existing salary of the principal investigator.

Applications due July 17, 2015

Medical College of Wisconsin
8701 Watertown Plank Road
Milwaukee, WI 53226
(414) 955-8296
Directions & Maps
© 2015

Page Updated 06/30/2015